Malignancies Clinical Trials in Guangzhou, Guangdong
14 recruitingGuangzhou, Guangdong, China
Showing 1–14 of 14 trials
Recruiting
Phase 1Phase 2
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Hematologic Malignancies
Sellas Life Sciences Group160 enrolled25 locationsNCT04588922
Recruiting
Phase 3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Solid TumorsHematologic Malignancies
Merck Sharp & Dohme LLC3,500 enrolled779 locationsNCT03486873
Recruiting
Phase 2
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Hematologic MalignanciesWaldenstroms MacroglobulinaemiaNon-Hodgkins Lymphoma+1 more
Merck Sharp & Dohme LLC490 enrolled121 locationsNCT04728893
Recruiting
Phase 3
Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial
VenentoclaxALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATIONMyeloid Malignancies+3 more
First Affiliated Hospital of Zhejiang University186 enrolled18 locationsNCT07396480
Recruiting
Phase 1
Exploratory Clinical Study of TCR-T for MAGE-A4-positive Mesenchymal Malignancies
Advanced Mesenchymal Malignancies
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University15 enrolled1 locationNCT07467122
Recruiting
Phase 1
This Study is a FIH Study Which is Required to Understand the PK Characteristics, MTD, RP2D and Safety Profile.
Hematologic Malignancies
Nanjing RegeneCore Biotech Co., Ltd.71 enrolled16 locationsNCT06756451
Recruiting
Phase 1
A Phase 1 Study of SKB571 in Subjects With Advanced Solid Tumors
Solid Malignancies
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.138 enrolled15 locationsNCT06725381
Recruiting
Phase 1
A Study of BRY812 for Injection Alone in Subjects With Advanced Malignancies
Advanced Malignancies
BioRay Pharmaceutical Co., Ltd.164 enrolled1 locationNCT06038058
Recruiting
Phase 2Phase 3
ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
Hematologic Malignancies
Beijing InnoCare Pharma Tech Co., Ltd.226 enrolled53 locationsNCT06378138
Recruiting
Phase 1Phase 2
Combination CAR-T Cell Therapy Targeting Hematological Malignancies
B-cell Malignancies
Shenzhen Geno-Immune Medical Institute100 enrolled4 locationsNCT03125577
Recruiting
Phase 1
The Study of ICP-248 in Patients With Mature B-cell Malignancies
Hematological Malignancies
Beijing InnoCare Pharma Tech Co., Ltd.191 enrolled22 locationsNCT05728658
Recruiting
Phase 1
A Study of DC50292A Tablet in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors
Solid Tumor Malignancies
Heronova Pharmaceuticals32 enrolled8 locationsNCT07071090
Recruiting
Phase 1
A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies
Advanced Solid TumorsHematological Malignancies
Hangzhou DAC Biotechnology Co., Ltd.110 enrolled1 locationNCT06224855
Recruiting
Phase 1
Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hematologic Malignancies
Advanced Solid Tumors and Hematologic Malignancies
Beijing InnoCare Pharma Tech Co., Ltd.146 enrolled3 locationsNCT05690581